# US 2020/0390800 A1 · Methods of preventing or treating neurogenic shock

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390800 A1
- Document ID: US20200390800A1
- Status: Published application
- Kind: A1
- Application number: 16/767,189
- Filed: 2018-11-29
- Published: 2020-12-17
- Earliest claimed: 2017-11-29
- Assignees: Ramot at Tel-Aviv University Ltd.; The Medical Research, Infrastruture and Health Services Fund of the Tel Aviv Medecal Center
- Applicants: Ramot at Tel-Aviv University Ltd.; The Medical Research, Infrastruture and Health Services Fund of the Tel Aviv Medecal Center
- Inventors: Shimon ROCHKIND; Zvi NEVO
- Web page: https://patentgrep.com/patent/US20200390800A1

## CPC

- A61K 31/728: Hyaluronic acid
- A61L 27/20: Polysaccharides
- A61K 9/0085: {Brain, e.g. brain implants; Spinal cord}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1745: {C-reactive proteins}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 38/446: {Superoxide dismutase (1.15)}
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/58: Materials at least partially resorbable by the body
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 5/0636: {T lymphocytes}
- C12Y 115/01001: Superoxide dismutase (1.15.1.1)
- A61K 2039/55516: {Proteins; Peptides}
- C12N 2533/80: Hyaluronan
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Methods of preventing or treating neurogenic shock are provided. Accordingly there is provided a method of treating neurogenic shock following nerve injury in a subject comprising implanting a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant, at or near the nerve injury of the subject. Also provided is a method of preventing or treating neurogenic shock following nerve injury in a subject comprising implanting within 48 hours following the nerve injury a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant, at or near the nerve injury of the subject.

## Claims

### Claim 1

A method of treating neurogenic shock following nerve injury in a subject demonstrating at least one symptom of neurogenic shock, the method comprising implanting a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant, at or near the nerve injury of the subject, thereby treating the neurogenic shock in the subject.

### Claim 2

(canceled)

### Claim 3

A method of preventing or treating neurogenic shock following nerve injury in a subject in need thereof, the method comprising implanting within 48 hours following the nerve injury a composition comprising a hyaluronic acid, a laminin polypeptide and an antioxidant, at or near the nerve injury of the subject, thereby preventing or treating the neurogenic shock in the subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein said implanting is effected within 24 hours following said nerve injury.

### Claim 5 (depends on 3)

The method of claim 3, wherein said implanting is effected within 12 hours following said nerve injury.

### Claim at position 6

6-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein said nerve injury is part of the central nervous system (CNS).

### Claim 11 (depends on 1)

The method of claim 1, wherein said nerve injury comprises spinal cord injury (SCI).

### Claim 12 (depends on 1)

The method of claim 1, wherein said nerve injury comprises traumatic brain injuries (TBI) or traumatic optic neuropathy (TON).

### Claim 13 (depends on 1)

The method of claim 1, wherein said subject is demonstrating at least one symptom of said neurogenic shock selected from the group consisting of instantaneous hypotension, warm flushed skin, priapism, peripheral vasodilatation, inability to get tachycardic, bradycardia, diaphragmatic breathing, respiratory arrest and organ dysfunction.

### Claim 14 (depends on 1)

The method of claim 1, wherein said subject is demonstrating at least one symptom of said neurogenic shock selected from the group consisting of hypotension, bradycardia and diaphragmatic breathing.

### Claim 15 (depends on 1)

The method of claim 1, wherein said antioxidant is superoxide dismutase (SOD).

### Claim 16 (depends on 15)

The method of claim 15, wherein said SOD comprises the amino acid sequence set forth by SEQ ID NO: 4.

### Claim 17 (depends on 1)

The method of claim 1, wherein said antioxidant is vitamin E.

### Claim 18 (depends on 1)

The method of claim 1, wherein said laminin polypeptide is set forth by SEQ ID NO: 1.

### Claim 19 (depends on 1)

The method of claim 1, wherein said antioxidant is superoxide dismutase (SOD) comprising the amino acid sequence set forth by SEQ ID NO: 4 and said laminin polypeptide is set forth by SEQ ID NO: 1.

### Claim 20 (depends on 1)

The method of claim 1, wherein said antioxidant is vitamin E and said laminin polypeptide is set forth by SEQ ID NO: 1.

### Claim 21 (depends on 1)

The method of claim 1, wherein said hyaluronic acid, said antioxidant and said laminin polypeptide are cross linked.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein said composition is formulated as a hydrogel.

### Claim 24 (depends on 23)

The method of claim 23, wherein said hyaluronic acid is provided at a concentration range of about 0.5-1.5% in said hydrogel.

### Claim 25 (depends on 23)

The method of claim 23, wherein said laminin polypeptide is provided at a concentration range of about 20-100 μg/ml in said hydrogel.

### Claim 26 (depends on 23)

The method of claim 23, wherein said antioxidant is provided at a concentration range of about 5-40 μg/ml in said hydrogel.

### Claim at position 24

27-28. (canceled)
